Milestone Pharmaceuticals Inc.MISTNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Financials Growth Insiders

Analyst Sentiment

Analysts lean bullish — 86% recommend buying.

Consensus Rating

Buy

7 analysts·Limited coverage

86%

Rating Distribution

Strong Buy

00%

Buy

686%

Hold

114%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 385% higher.

Bear Case

$8.00

+385%

Consensus

$8.00

+385%

Bull Case

$8.00

+385%

Price Range7 analysts

Low

Consensus

High

$8.00

Current Target

Current Price

$1.65

Upside to Target

$6.35

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.51(3 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev-21.32%

EPS—

FY2028

Rev+455.56%

EPS—

FY2029

Rev+64.94%

EPS—

Earnings Surprises

Beat rate:67%(8/12 quarters)

Avg surprise:+1.0%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Dec 16, 2025Wells Fargo

Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo

Target:$8.00

+241.9%from $2.34

Dec 15, 2025H.C. Wainwright

Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright

Target:$8.00

+210.7%from $2.58

Apr 22, 2022Piper Sandler

Piper Sandler Upgrades Milestone Pharmaceuticals to Overweight, Raises Price Target to $10

Target:$10.00

+39.9%from $7.15

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance